127 related articles for article (PubMed ID: 38150107)
1. Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity.
Mondal D; Bagchi A; Biswas S; Dagar T; Biswas A; Bagchi A; De S
ACS Appl Bio Mater; 2024 Jan; 7(1):369-378. PubMed ID: 38150107
[TBL] [Abstract][Full Text] [Related]
2. Addressing the Superior Drug Delivery Performance of Bilosomes─A Microscopy and Fluorescence Study.
Mondal D; Mandal RP; De S
ACS Appl Bio Mater; 2022 Aug; 5(8):3896-3911. PubMed ID: 35924346
[TBL] [Abstract][Full Text] [Related]
3. Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model.
Boomkamp SD; McGrath MA; Houslay MD; Barnett SC
Br J Pharmacol; 2014 May; 171(9):2385-98. PubMed ID: 24467222
[TBL] [Abstract][Full Text] [Related]
4. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG).
Wang L; Huang X; Jing H; Ma C; Wang H
Food Res Int; 2021 Nov; 149():110631. PubMed ID: 34600647
[TBL] [Abstract][Full Text] [Related]
5. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.
Gobejishvili L; Barve S; Breitkopf-Heinlein K; Li Y; Zhang J; Avila DV; Dooley S; McClain CJ
J Pharmacol Exp Ther; 2013 Oct; 347(1):80-90. PubMed ID: 23887098
[TBL] [Abstract][Full Text] [Related]
6. Unlocking the Potential of Bilosomes and Modified Bilosomes: a Comprehensive Journey into Advanced Drug Delivery Trends.
Nayak D; Rathnanand M; Tippavajhala VK
AAPS PharmSciTech; 2023 Nov; 24(8):238. PubMed ID: 37989979
[TBL] [Abstract][Full Text] [Related]
7. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.
Gong MF; Wen RT; Xu Y; Pan JC; Fei N; Zhou YM; Xu JP; Liang JH; Zhang HT
Psychopharmacology (Berl); 2017 Oct; 234(20):3143-3151. PubMed ID: 28748375
[TBL] [Abstract][Full Text] [Related]
9. Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study.
Fang CL; Wen CJ; Aljuffali IA; Sung CT; Huang CL; Fang JY
J Control Release; 2015 Sep; 213():69-78. PubMed ID: 26164036
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.
Korhonen R; Hömmö T; Keränen T; Laavola M; Hämäläinen M; Vuolteenaho K; Lehtimäki L; Kankaanranta H; Moilanen E
Br J Pharmacol; 2013 Aug; 169(7):1525-36. PubMed ID: 23849041
[TBL] [Abstract][Full Text] [Related]
11. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.
Wen RT; Zhang M; Qin WJ; Liu Q; Wang WP; Lawrence AJ; Zhang HT; Liang JH
Alcohol Clin Exp Res; 2012 Dec; 36(12):2157-67. PubMed ID: 22671516
[TBL] [Abstract][Full Text] [Related]
12. Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis.
Gobejishvili L; Rodriguez WE; Bauer P; Wang Y; Soni C; Lydic T; Barve S; McClain C; Maldonado C
Drug Des Devel Ther; 2022; 16():1301-1309. PubMed ID: 35535222
[TBL] [Abstract][Full Text] [Related]
13. Rolipram Rescues Memory Consolidation Deficits Caused by Sleep Deprivation: Implication of the cAMP/PKA and cAMP/Epac Pathways.
Maher A; El Sayed N; Nafea H; Gad M
CNS Neurol Disord Drug Targets; 2022; 21(7):631-639. PubMed ID: 34397335
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR.
Mukherjee P; Bagchi A; Banerjee A; Roy H; Bhattacharya A; Biswas A; Chatterji U
J Cell Biochem; 2022 Dec; 123(12):1980-1996. PubMed ID: 36063486
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.
Yeo CD; Kim JW; Ha JH; Kim SJ; Lee SH; Kim IK; Kim YK
Exp Lung Res; 2014 Dec; 40(10):500-6. PubMed ID: 25275945
[TBL] [Abstract][Full Text] [Related]
16. Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.
Campos-Toimil M; Keravis T; Orallo F; Takeda K; Lugnier C
Br J Pharmacol; 2008 May; 154(1):82-92. PubMed ID: 18311187
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior induced by cues or heroin priming in rats.
Lai M; Zhu H; Sun A; Zhuang D; Fu D; Chen W; Zhang HT; Zhou W
Int J Neuropsychopharmacol; 2014 Sep; 17(9):1397-407. PubMed ID: 24832929
[TBL] [Abstract][Full Text] [Related]
18. The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway.
Dong XL; Wang YH; Xu J; Zhang N
Sci Rep; 2021 Oct; 11(1):19737. PubMed ID: 34611179
[TBL] [Abstract][Full Text] [Related]
19. Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges.
Zarenezhad E; Marzi M; Abdulabbas HT; Jasim SA; Kouhpayeh SA; Barbaresi S; Ahmadi S; Ghasemian A
J Funct Biomater; 2023 Sep; 14(9):. PubMed ID: 37754867
[TBL] [Abstract][Full Text] [Related]
20. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
